Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04649359




Registration number
NCT04649359
Ethics application status
Date submitted
6/11/2020
Date registered
2/12/2020
Date last updated
30/04/2024

Titles & IDs
Public title
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Scientific title
MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY
Secondary ID [1] 0 0
2020-004533-21
Secondary ID [2] 0 0
C1071003
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Elranatamab (PF-06863135)

Experimental: Elranatamab (cohort A) - BCMA-CD3 bispecific antibody

Experimental: Elranatamab (cohort B) - BCMA-CD3 bispecific antibody


Treatment: Drugs: Elranatamab (PF-06863135)
BCMA-CD3 bispecific antibody
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria
Timepoint [1] 0 0
From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 16 months)
Secondary outcome [1] 0 0
Cohort A Only: Objective Response Rate as Per IMWG Criteria by BICR for Participants With Extramedullary Disease (EMD) at Baseline
Timepoint [1] 0 0
From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 16 months)
Secondary outcome [2] 0 0
Cohort A Only: Objective Response Rate as Per IMWG Criteria by BICR for Participants Without EMD at Baseline
Timepoint [2] 0 0
From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 16 months)
Secondary outcome [3] 0 0
Duration of Response (DOR) as Per IMWG Criteria by BICR
Timepoint [3] 0 0
From first documentation of objective response subsequently confirmed until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 20.14 months)
Secondary outcome [4] 0 0
Duration of Response as Per IMWG Criteria by Investigator Assessment
Timepoint [4] 0 0
From first documentation of objective response subsequently confirmed until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 20.14 months)
Secondary outcome [5] 0 0
Complete Response Rate (CRR) as Per IMWG Criteria by BICR
Timepoint [5] 0 0
From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 20.14 months)
Secondary outcome [6] 0 0
Complete Response Rate as Per IMWG Criteria by Investigator Assessment
Timepoint [6] 0 0
From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 20.14 months)
Secondary outcome [7] 0 0
Objective Response Rate as Per IMWG Criteria by Investigator Assessment
Timepoint [7] 0 0
From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 20.14 months)
Secondary outcome [8] 0 0
Duration of Complete Response (DOCR) as Per IMWG Criteria by BICR
Timepoint [8] 0 0
From first documentation of sCR/CR subsequently confirmed until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 20.14 months)
Secondary outcome [9] 0 0
Duration of Complete Response (DOCR) as Per IMWG Criteria by Investigator Assessment
Timepoint [9] 0 0
From first documentation of objective sCR/CR subsequently confirmed until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 20.14 months)
Secondary outcome [10] 0 0
Progression Free Survival (PFS) as Per IMWG Criteria by BICR
Timepoint [10] 0 0
From date of first dose until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 20.14 months)
Secondary outcome [11] 0 0
Progression Free Survival (PFS) as Per IMWG Criteria by Investigator Assessment
Timepoint [11] 0 0
From date of first dose until confirmed PD or death due to any cause, or start of new anticancer therapy, whichever occurred first, or censoring (up to approximately 20.14 months)
Secondary outcome [12] 0 0
Overall Survival (OS)
Timepoint [12] 0 0
From the date of first dose until death due to any cause. Participants not known to have died were censored on the date of last known alive (up to approximately 20.14 months)
Secondary outcome [13] 0 0
Time-to-Response (TTR) as Per IMWG Criteria by BICR
Timepoint [13] 0 0
From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 16 months)
Secondary outcome [14] 0 0
Time-to-Response (TTR) as Per IMWG Criteria by Investigator Assessment
Timepoint [14] 0 0
From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 20.14 months)
Secondary outcome [15] 0 0
Minimal Residual Disease (MRD) Negativity Rate Per IMWG Sequencing Criteria
Timepoint [15] 0 0
From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 20.14 months)
Secondary outcome [16] 0 0
Number of Participants With Treatment Emergent Adverse Events (TEAE) Graded by National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Timepoint [16] 0 0
From the date of first dose up to 90 days after last dose or new anticancer therapy whichever occurred first (up to approximately 20.14 months)
Secondary outcome [17] 0 0
Number of Participants With Shift From Grade Less Than or Equal to (<=) 2 at Baseline to Grade 3 or 4 Post -Baseline in Laboratory Parameters by NCI CTCAE v 5.0
Timepoint [17] 0 0
From the date of first dose up to 90 days after last dose or new anticancer therapy whichever occurred first (up to approximately 20.14 months)
Secondary outcome [18] 0 0
Number of Participants With Cytokine Release Syndrome (CRS) Graded According to American Society for Transplantation and Cellular Therapy (ASTCT) Criteria
Timepoint [18] 0 0
From the date of first dose up to 90 days after last dose or new anticancer therapy whichever occurred first (up to approximately 20.14 months)
Secondary outcome [19] 0 0
Number of Participants With Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS) Graded According to American Society for Transplantation and Cellular Therapy (ASTCT) Criteria
Timepoint [19] 0 0
From the date of first dose up to 90 days after last dose or new anticancer therapy whichever occurred first (up to approximately 20.14 months)
Secondary outcome [20] 0 0
Serum Concentration of Elranatamab
Timepoint [20] 0 0
Pre-dose on Day 1 of Cycle 4 and Pre-dose on Day 1 of Cycle 7
Secondary outcome [21] 0 0
Percentage of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb) Against Elranatamab
Timepoint [21] 0 0
From the date of first dose up to 20.14 months

Eligibility
Key inclusion criteria
- Diagnosis of multiple myeloma (IMWG criteria, Rajkumar et al, 2014)

- Measurable disease, as defined by at least 1 of the following:

1. Serum M-protein >0.5 g/dL by SPEP

2. Urinary M-protein excretion >200 mg/24 hours by UPEP

3. Serum immunoglobulin FLC=10 mg/dL (=100 mg/L) AND abnormal serum immunoglobulin
kappa to lambda FLC ratio

- Refractory to at least one IMiD

- Refractory to at least one PI

- Refractory to at least one anti-CD38 antibody

- Relapsed/refractory to last anti-myeloma regimen

- Cohort A: has not received prior BCMA-directed therapy

- Cohort B: has received prior BCMA-directed therapy (ADC or CAR T cells)

- ECOG performance status =2

- Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade =1

- Not pregnant and willing to use contraception
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Smoldering multiple myeloma

- Active Plasma cell leukemia

- Amyloidosis

- POEMS syndrome

- Stem cell transplant within 12 weeks prior to enrollment

- Active HBV, HCV, SARS-CoV2, HIV, or any active, uncontrolled bacterial, fungal, or
viral infection

- Any other active malignancy within 3 years prior to enrollment, except for adequately
treated basal cell or squamous cell skin cancer, or carcinoma in situ.

- Previous administration with an investigational drug within 30 days or 5 half-lives
preceding the first dose of study intervention used in this study (whichever is
longer)

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/02/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/12/2025
Actual
Sample size
Target
Accrual to date
Final
188
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Epworth Healthcare - East Melbourne
Recruitment hospital [2] 0 0
St Vincent's Hospital (Melbourne) - Fitzroy
Recruitment hospital [3] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [4] 0 0
The Alfred - Melbourne
Recruitment hospital [5] 0 0
Epworth Healthcare - Richmond
Recruitment postcode(s) [1] 0 0
3002 - East Melbourne
Recruitment postcode(s) [2] 0 0
3065 - Fitzroy
Recruitment postcode(s) [3] 0 0
3004 - Melbourne
Recruitment postcode(s) [4] 0 0
3050 - Richmond
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Indiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Iowa
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
South Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Texas
Country [15] 0 0
Belgium
State/province [15] 0 0
Antwerpen
Country [16] 0 0
Belgium
State/province [16] 0 0
Edegem
Country [17] 0 0
Belgium
State/province [17] 0 0
Yvoir
Country [18] 0 0
Canada
State/province [18] 0 0
Alberta
Country [19] 0 0
Canada
State/province [19] 0 0
Quebec
Country [20] 0 0
France
State/province [20] 0 0
Lille
Country [21] 0 0
France
State/province [21] 0 0
Nantes Cedex 1
Country [22] 0 0
France
State/province [22] 0 0
Paris Cedex 12
Country [23] 0 0
France
State/province [23] 0 0
Paris
Country [24] 0 0
France
State/province [24] 0 0
Pierre Benite Cedex
Country [25] 0 0
France
State/province [25] 0 0
Poitiers Cedex
Country [26] 0 0
Germany
State/province [26] 0 0
Chemnitz
Country [27] 0 0
Germany
State/province [27] 0 0
Hamburg
Country [28] 0 0
Germany
State/province [28] 0 0
Heidelberg
Country [29] 0 0
Germany
State/province [29] 0 0
Kiel
Country [30] 0 0
Japan
State/province [30] 0 0
Aichi
Country [31] 0 0
Japan
State/province [31] 0 0
Gunma
Country [32] 0 0
Japan
State/province [32] 0 0
Hyogo
Country [33] 0 0
Japan
State/province [33] 0 0
Iwate
Country [34] 0 0
Japan
State/province [34] 0 0
Miyagi
Country [35] 0 0
Japan
State/province [35] 0 0
Tokyo
Country [36] 0 0
Japan
State/province [36] 0 0
Yamagata
Country [37] 0 0
Poland
State/province [37] 0 0
Bydgoszcz
Country [38] 0 0
Poland
State/province [38] 0 0
Poznan
Country [39] 0 0
Poland
State/province [39] 0 0
Wroclaw
Country [40] 0 0
Spain
State/province [40] 0 0
A Coruna
Country [41] 0 0
Spain
State/province [41] 0 0
Barcelona
Country [42] 0 0
Spain
State/province [42] 0 0
Navarra
Country [43] 0 0
Spain
State/province [43] 0 0
Madrid
Country [44] 0 0
Spain
State/province [44] 0 0
Valencia
Country [45] 0 0
United Kingdom
State/province [45] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can
provide clinical benefit in participants with relapsed/refractory multiple myeloma.
Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and
BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04649359
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04649359